Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.
NCT05104125 is registered in ClinicalTrials.gov with Ascletis Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.
- Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 12, 2022
- Completion date
- April 10, 2023
- Enrollment
- 180 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.